IN VITRO ANALYSIS OF THE IMPACT OF INHIBITORS ON THE PROCOAGULANT EFFECTS OF BYPASS AGENTS OR HEMOSTATIC FACTORS IN COMBINATION WITH EMICIZUMAB

Idelvion (albutrepenonacog alfa) - CSL Behring

Advate (octocog alfa) - Takeda

Rixubis (nonacog gamma) - Baxter Healthcare, Takeda

Hemlibra (emicizumab-kxwh) - Roche

BeneFix (nonacog alfa) - Pfizer

NovoSeven (eptacog alfa) - Novo Nordisk

https://library.ehaweb.org/eha/2022/eha2022-congress/357160/abel.dos.santos.in.vitro.analysis.of.the.impact.of.inhibitors.on.the.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Aot_id%3D26871%2Amarker%3D1751%2Afeatured%3D17676

Abel Dos Santos Ortas; Elena García Arias-Salgado; Elena Monzón Manzano; Paula Acuña; María Teresa Álvarez Roman; Mónica Martín Salces; María Isabel Rivas Pollmar; Eduardo García Pérez; Mar Gutiérrez Alvariño; Alberto Gonzalez Ceberino; Sara García Barcenilla; Nora Butta; Víctor Jiménez Yuste

May 13, 2022